Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Sensorion SA
ALSENSensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France. Address: 375, rue du Professeur Joseph Blayac, Montpellier, France, 34080
Analytics
Zielpreis von Wall Street
2.27 EURKGV
–Dividendenrendite
–Schlüsselzahlen ALSEN
- Gewinnspanne
- Gesamtumsatz
- Bruttogewinn
- Nettogewinn
Dividenden-Analyse ALSEN
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende ALSEN
- Auszahlungsquote
- Dividends
- Dividendenrendite
Bewertung der Aktie ALSEN
- KUV
- KGV
- Kurs-Buchwert-Verhältnis
- Liquiditätsgrad
- Verschuldungsgrad
Finanzen ALSEN
Ergebnisse | 31.12.2015 | 31.12.2016 | 31.12.2017 | 31.12.2018 | 31.12.2019 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | 31.12.2024 | Dynamik | |
Gesamtumsatz | 155 528 EUR | 17 279 EUR | 1 910 091 EUR | 2 202 352 EUR | 2 425 735 EUR | 2 322 465 EUR | 4 210 025 EUR | 4 871 524 EUR | 4 683 334 EUR | 4 683 334 EUR * | ||
Betriebseinnahmen | -5 255 391 EUR | -8 992 151 EUR | -9 485 769 EUR | -12 150 227 EUR | -13 150 168 EUR | -11 147 933 EUR | -19 106 582 EUR | -27 750 896 EUR | -22 029 670 EUR | -28 043 346 EUR | ||
Nettogewinn - (CF) | -4 217 177 EUR | -7 319 136 EUR | -9 564 185 EUR | -12 194 497 EUR | -11 943 854 EUR | -8 865 027 EUR | -14 946 171 EUR | -22 916 818 EUR | -21 785 559 EUR | -25 644 934 EUR | ||
Normalisiertes Basis-EPS | -1.09 EUR | -1.18 EUR | -1.46 EUR | -1.18 EUR | -0.71 EUR | -0.16 EUR | -0.21 EUR | -0.32 EUR | -0.18 EUR | -0.18 EUR * | ||
Dividende pro Aktie | 0.00 EUR | 0.00 EUR | 0.00 EUR | 0.00 EUR | 0.00 EUR | 0.00 EUR | 0.00 EUR | 0.00 EUR | 0.00 EUR | 0.00 EUR | ||
Auszahlungsquote | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Gesamtvermögen | 16 311 596 EUR | 11 702 165 EUR | 11 020 428 EUR | 9 348 037 EUR | 37 613 379 EUR | 67 016 036 EUR | 58 273 485 EUR | 38 440 734 EUR | 45 917 203 EUR | 88 152 734 EUR | ||
Gesamtverbindlichkeiten | 3 653 801 EUR | 3 218 574 EUR | 3 793 430 EUR | 5 881 925 EUR | 24 567 681 EUR | 9 404 383 EUR | 14 844 920 EUR | 16 845 169 EUR | 13 060 698 EUR | 16 923 168 EUR | ||
Verschuldungsgrad | 0.22 | 0.28 | 0.34 | 0.63 | 0.65 | 0.14 | 0.26 | 0.44 | 0.28 | 0.19 | ||
Gesamtumlaufvermögen | 15 130 301 EUR | 10 305 544 EUR | 9 824 454 EUR | 8 196 878 EUR | 35 910 745 EUR | 65 560 481 EUR | 56 157 586 EUR | 35 304 813 EUR | 42 721 151 EUR | 84 623 742 EUR | ||
Gesamtverbindlichkeiten | 2 720 289 EUR | 2 196 810 EUR | 2 161 612 EUR | 4 285 484 EUR | 22 556 398 EUR | 4 224 043 EUR | 10 396 957 EUR | 13 421 714 EUR | 10 148 144 EUR | 13 481 068 EUR | ||
Liquiditätsgrad | 5.56 | 4.69 | 4.55 | 1.91 | 1.59 | 15.52 | 5.40 | 2.63 | 4.21 | 6.28 | ||
Schnellliquiditätsgrad | 5.56 | 4.69 | 4.55 | 3.06 | 1.57 | 15.12 | 5.24 | 2.58 | 4.21 | 6.28 | ||
ROA | -25.85 % | -62.55 % | -86.79 % | -130.45 % | -31.75 % | -13.23 % | -25.65 % | -59.62 % | -47.45 % | -29.09 % | ||
FFO-Zinsdeckung | -181.04 | -1 480.80 | -41.55 | -77.35 | -8.19 | -60.71 | -80.15 | -113.04 | -105.66 | -105.66 * | ||
KGV - P/E (LTM) | -8.71 | -4.28 | -3.04 | -0.98 | -1.34 | -11.40 | -10.60 | -1.25 | -2.65 | -2.65 * | ||
Dividendenrendite (LTM) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Rückkaufrendite (LTM) | - | -59.47 % | -5.84 % | -58.34 % | -63.39 % | -225.81 % | -31.16 % | - | -67.12 % | -67.12 % * |